Clinical trial
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to…
NCT00262236 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00262236 |
|---|---|
| Title | Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension |
| Official title | A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Aliskiren |
| Enrollment | 693 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Dec 6, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: